Comparison of risk factors for viral and nonviral asthma exacerbations

Amaziah T. Coleman, Daniel J. Jackson, Ronald E. Gangnon, Michael D. Evans, Robert F. Lemanske, James E. Gern

Research output: Contribution to journalArticlepeer-review

7 Scopus citations
Original languageEnglish (US)
Pages (from-to)1127-1129.e4
JournalJournal of Allergy and Clinical Immunology
Issue number4
StatePublished - Oct 2015
Externally publishedYes

Bibliographical note

Funding Information:
Disclosure of potential conflict of interest: D. J. Jackson has received research support from the National Heart, Lung, and Blood Institute (NHLBI) and has received consultancy fees from GlaxoSmithKline and Genentech. R. E. Gangnon has received research support from the NHLBI. M. D. Evans has received research support from the National Institutes of Health (NIH). R. F. Lemanske, Jr, reports grants from the University of Wisconsin during the conduct of the study; other from board membership and personal fees from the University of Wisconsin; grants from the NHBLI; personal fees from Merck, Sepracor, SA Boney and Associates, GlaxoSmithKline, the American Institute of Research, Genentech, Double Helix Development, and Boehringer Ingelheim, Michigan Public Health, Allegheny General Hospital, the AAP, West Allegheny Health, California Chapter 4, the Colorado Allergy Society, the Pennsylvania Allergy Society, Howard Pilgrim Health, the California Society of Allergy, the NYC Allergy Society, the World Allergy Organization, APAPARI, Elsevier, UpToDate, the Kuwait Allergy Society, Lurie Children's Hospital, Boston Children's Hospital, Health Star Communications, LA Children's Hospital, and Northwestern University, and the Western Society of Allergy, Asthma, and Immunology, the American Academy of Allergy, Asthma & Immunology outside the submitted work; and grants from Pharmaxis outside the submitted work. J. E. Gern has received research support from the NIH, GlaxoSmithKline, and Merck and has received consultancy fees from GlaxoSmithKline, Johnson & Johnson, Merck, MedImmune, Boehringer Ingelheim, Gilead, and Genentech. A. T. Coleman declares no relevant conflicts of interest.

Funding Information:
Supported by the National Institutes of Health (grant nos. P01 HL70831 and UL1TR000427 ).

Cite this